Stocktoria
Sana Biotechnology, Inc. SANA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-04
Chart by TradingView
1/9
Piotroski F — financial health
-16.73
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Net income | -$244.2M | -$266.8M | -$283.3M | -$269.5M | -$355.9M |
| Operating cash flow | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$251.1M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$280.9M |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.1B |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
| Shareholders' equity | $160.9M | $250.5M | $287.5M | $499.3M | $728.5M |
| Ratios | |||||
| Return on assets | -58.6% | -53.2% | -50.1% | -32.8% | -31.5% |
| Return on equity | -151.8% | -106.5% | -98.5% | -54.0% | -48.9% |
| Current ratio | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,451,200 | $4.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.73 (distress)
- Working capital / assets 0.168
- Retained earnings / assets -4.435
- EBIT / assets -0.6
- Equity / liabilities 0.628
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001770121 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.